AbbVie settles with generic drugmakers for Rinvoq (ABBV:NYSE)

Group 1 - AbbVie has reached settlements with all generic drugmakers regarding litigation over Rinvoq, a significant product in its immunology portfolio [4] - The settlements resolve challenges posed by generic manufacturers planning to introduce copycat versions of Rinvoq [4] - This development is expected to protect AbbVie's market position and revenue from Rinvoq, which is crucial for its immunology franchise [4]